# Rapamycin Plus Bevacizumab in Advanced Cancers

> **NCT00667485** · PHASE1 · COMPLETED · sponsor: **University of Chicago** · enrollment: 28 (actual)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** Rapamycin (liquid)
- **DRUG:** Bevacizumab
- **DRUG:** Rapamycin (Tablets)

## Key facts

- **NCT ID:** NCT00667485
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00667485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00667485, "Rapamycin Plus Bevacizumab in Advanced Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00667485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*